The relatively small sample size, and particularly the low proportion of BRAF-mutant melanomas, limited the statistical power to conduct multivariable analyses or calculate reliable diagnostic performance metrics (AUC, sensitivity, specificity). The gene discussed is BRAF; the disease is melanoma.